|Dr. Vasant Narasimhan||Chief Executive Officer||5.85M||N/A||1976|
|Mr. Harry Kirsch||Chief Financial Officer||2.96M||N/A||1965|
|Dr. Steffen Lang Ph.D.||President of Operations||2.43M||N/A||1967|
|Dr. Klaus Moosmayer Ph.D.||Chief Ethics, Risk & Compliance Officer||1.61M||N/A||1968|
|Ms. Karen L. Hale||Chief Legal Officer||2.44M||N/A||1968|
|Dr. Robert Kowalski Pharm.D.||Chief People & Organization Officer||2.18M||N/A||1968|
|Mr. Victor Bulto||President of US||2.39M||N/A||N/A|
|Dr. Shreeram Aradhye M.D.||President of Global Drug Development & Chief Medical Officer||2.38M||N/A||1963|
|Mr. Aharon Gal Ph.D.||Chief Strategy & Growth Officer||6.54M||N/A||N/A|
|Dr. Fiona H. Marshall Ph.D.||President of BioMedical Research||5.3M||N/A||1964|
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Novartis AG’s ISS Governance QualityScore as of December 1, 2023 is 1. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 1; Compensation: 1.